Question · asked by 1 review
Gemcitabine plus cisplatin vs S‐1 plus cisplatin: Serious adverse events
- Population
- people with advanced biliary tract carcinomas
- Intervention
- Gemcitabine plus cisplatin
- Comparison
- S‐1 plus cisplatin
- Outcome
- Serious adverse events
The review found no eligible studies for this question.
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Gemcitabine plus cisplatin vs S‐1 plus cisplatin Serious adverse events · people with advanced biliary tract carcinomas The review found no eligible studies for this question. Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas (2018) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.